Analysts on Wall Street project that United Therapeutics (UTHR) will announce quarterly earnings of $6.10 per share in its forthcoming report, representing an increase of 39.9% year over year. Revenues are projected to reach $725.32 million, increasing 18% from the same quarter last year.
The consensus EPS estimate for the quarter has been revised 0.5% higher over the last 30 days to the current level. This reflects how the analysts covering the stock have collectively reevaluated their initial estimates during this timeframe.
Ahead of a company's earnings disclosure, it is crucial to give due consideration to changes in earnings estimates. These revisions serve as a noteworthy factor in predicting potential investor reactions to the stock. Numerous empirical studies consistently demonstrate a strong relationship between trends in earnings estimate revision and the short-term price performance of a stock.
While investors typically use consensus earnings and revenue estimates as a yardstick to evaluate the company's quarterly performance, scrutinizing analysts' projections for some of the company's key metrics can offer a more comprehensive perspective.
With that in mind, let's delve into the average projections of some United Therapeutics metrics that are commonly tracked and projected by analysts on Wall Street.
The collective assessment of analysts points to an estimated 'Revenues- Adcirca' of $6.10 million. The estimate points to a change of -10.3% from the year-ago quarter.
The consensus estimate for 'Revenues- Orenitram' stands at $109.01 million. The estimate points to a change of +29.6% from the year-ago quarter.
The combined assessment of analysts suggests that 'Revenues- Remodulin' will likely reach $117.28 million. The estimate indicates a year-over-year change of +1.9%.
According to the collective judgment of analysts, 'Revenues- Tyvaso' should come in at $425.28 million. The estimate points to a change of +99% from the year-ago quarter.
It is projected by analysts that the 'Revenues- Unituxin' will reach $59.93 million. The estimate suggests a change of +10.6% year over year.
Analysts' assessment points toward 'Revenues- Rest-of-World' reaching $30.17 million. The estimate points to a change of +4.7% from the year-ago quarter.
Analysts predict that the 'Revenues- United States' will reach $681.36 million. The estimate indicates a change of +16.3% from the prior-year quarter.
View all Key Company Metrics for United Therapeutics here>>>
Over the past month, United Therapeutics shares have recorded returns of -2.6% versus the Zacks S&P 500 composite's -0.5% change. Based on its Zacks Rank #4 (Sell), UTHR will likely underperform the overall market in the upcoming period. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
United Therapeutics Corporation (UTHR) : Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.